Current Report Filing (8-k)
December 10 2019 - 8:33AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): December 6, 2019
One
World Pharma, Inc.
(Exact
name of registrant as specified in charter)
Nevada
|
|
333-200529
|
|
61-1744826
|
(State
or other Jurisdiction
of
Incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
3471
West Oquendo Road, Suite 301 Las Vegas, NV
|
|
89118
|
(Address
of principal executive offices)
|
|
(zip
code)
|
Registrant’s
telephone number, including area code: (800) 605-3201
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under
any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
N/A
|
|
N/A
|
|
N/A
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR
§230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 1.01. Entry into a Material Definitive Agreement.
On
December 6, 2019, One World Pharma, Inc. (the “Company”), through its wholly-owned subsidiary OWP Ventures, Inc.,
acquired 51% of the outstanding shares of capital stock (the “Shares”) of Colcannapy S.A.S., a Colombian company (“Colcannapy”),
for a purchase price of US$102,000, pursuant to a Share Purchase Agreement (the “Purchase Agreement”) among OWP Ventures,
Inc. and Colcannapy’s shareholders.
Concurrently,
with the Company’s acquisition of the Shares, Federación Colombiana de Consejos Regionales (“Fedecoré”)
purchased the remaining 49% of Colcannapy’s outstanding shares of capital stock from Colcannapy’s shareholders, so
that the Company and Fedecoré are now the only shareholders of Colcannapy.
Colcannapy
is the holder of a Colombian seed license and 23 registered Colombian cultivars.
Item
8.01. Other Events.
On
December 9, 2019, the Company issued a press release announcing its joint venture relationship with Fedecoré, which has
been filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item
9.01. Financial Statements and Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
One
World Pharma, Inc.
|
|
|
|
Date:
December 10, 2019
|
|
|
|
|
By:
|
/s/
Craig Ellins
|
|
|
Craig
Ellins
|
|
|
Chief
Executive Officer
|
One World Products (QB) (USOTC:OWPC)
Historical Stock Chart
From Mar 2024 to Apr 2024
One World Products (QB) (USOTC:OWPC)
Historical Stock Chart
From Apr 2023 to Apr 2024